Osimertinib's Benefits in NSCLC Can Extend Beyond First Line

Patients with EGFR-mutated NSCLC who progress on first-line osimertinib live longer without disease worsening when the drug is maintained alongside chemotherapy second line.
Medscape Medical News

source https://www.medscape.com/viewarticle/osimertinibs-benefits-nsclc-can-extend-beyond-first-line-2025a1000nlc?src=rss

Comments

Popular posts from this blog

New AAFP practice guideline sets blood pressure targets for adults with hypertension

RA and RA-ILD Linked to Higher Lung Cancer Risk

A Large Multicenter Prospective Study of Community-Onset Healthcare Associated Bacteremic Urinary Tract Infections in the Era of Multidrug Resistance: Even Worse than Hospital Acquired Infections?